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osting by EAbstract In the present study the antihistaminic activity of tricyclic benzothieno 1,2,3-triazine
derivatives namely CP-3 (3-(phenyl)-5,6,7,8-tetrahydro,3H-benzo[4,5] thieno [2,3-d][1,2,3] triazin-
4-one), CP-5 (3-(3-methyl phenyl)-5,6,7,8-tetrahydro,3H-benzo[4,5] thieno [2,3-d][1,2,3] triazin-4-
one) and CP-8 (3-(4-chloro phenyl)-5,6,7,8-tetrahydro,3H-benzo[4,5] thieno [2,3-d][1,2,3] triazin-
4-one) were evaluated using in vitro (isolated guinea pig ileum) and in vivo (bronchodilator activity
in guinea pigs) models and the sedative potential of the test compounds were evaluated using acto-
photometer in mice. In in vitro antihistaminic study, the CP-3, CP-5, CP-8 and chlorpheniramine
maleate (CPM) have shown a rightward shift in concentration response curve (CRC) of histamine
with a change in EC50 values of histamine in all the four tissue preparations. The slope obtained in
the schild plot indicated that CP-5, CP-8 and CPM were competitive in nature for H1-receptors.
However, CP-3 has shown non-competitive antagonism. In in vivo antihistaminic study, the CP-
3, CP-5, CP-8 and CPM have shown mean increase in exposition time against histamine challengeo. 387/511/A, Megalabeedi,
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46 G.L. Viswanatha et al.compared to control group (p< 0.001). All the test drugs (10 mg/kg) and CPM (2 mg/kg) have
offered a signiﬁcant (p< 0.001) protection against preconvulsive dyspnoea (PCD) compared to
control. In conclusion, all the test drugs have shown very good antihistaminic activity and the test
drugs have very little sedative action compared to CPM.
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Allergy is one of the common diseases that affects mankind
with diverse manifestations, allergy can refer to several kinds
of immune reactions including type-I hypersensitivity reactions
and activation of mast cells (Ring et al., 2001). The mast cell is
a key effector cell in allergic inﬂammation and the release of
histamine from activated mast cells and basophils contributes
signiﬁcantly to the symptoms of allergic rhinitis, conjunctivitis,
urticaria and other allergic reactions including allergic asthma
anaphylaxis, autoimmune hemolytic anemia, erythroblastosis
fetalis, pernicious anemia, immune complex glomerulonephri-
tis, rheumatoid arthritis, serum sickness, contact dermatitis
and temporal arteritis (Larson et al., 2007). Currently antihis-
tamines, glucocorticoids and mast cell stabilizers are widely
prescribed for the management of these allergic reactions,
but these drugs exhibit a high side effect proﬁle which includes
sedation, diminished alertness and concentration, light headed-
ness, motor in coordination, fatigue and tendency to fall asleep
(Klaassen., 2001).
The substituted triazines are reported for many uses like
anti-inﬂammatory activity (Daidone et al., 1998), analgesic
activity (Daidone et al., 1998), purine antagonism activity (Bie-
sele, 1952), anti cancer and trypanocidal activities (Gatta et al.,
1989), antineoplastic activity (Dattolo et al., 1989), inhibition
of nitric oxide and eicosanoid biosynthesis (Quintela et al.,
1999), 5-HT3 receptor antagonists with gastric motility
enhancement activity (David, 1990), antianaphylatic activity
(Siegfried et al., 1990), anti platelet aggregation activity (Anto-
nio et al., 1992), anti thrombotic and elastase inhibitor activity
(Thomas et al., 1995), antiallergic activity (Youssefyeh et al.,
1984), xanthine oxidase inhibitory activity (Shaw and Woolley,
1952), antiviral/antitumor activity (Manfredini et al., 1992),
fungicidal activity (Anthony et al., 1993), antimicrobial activ-
ity and antineoplastic activity (Monge et al., 1991).
The 1,2,3-triazines are the class of heterocyclic compounds,
unlike other triazines there is very minimal research that has
been carried out on this class of compounds and based on
the structural similarities of these compounds with the other
triazines like 1,2,4-triazines and 1,3,5-triazine, it is thought
that 1,2,3-triazine derivatives may also found to possess pros-
taglandin inhibition property, analgesic, anti-inﬂammatory
and antihistaminic properties. Based on the results of prelimin-
ary antihistaminic pilot study, the present study was under
taken to investigate the synthesized tricyclic benzothieno
1,2,3-triazines for their anti-histaminic activity.
2. Materials and methods
2.1. Drugs, chemicals and instruments
Histamine hydrochloride (Otto Kemi, Mumbai) and Chlor-
pheniramine maleate (Alfa Labs, Pigdambari). The solventsand chemicals used for the synthesis of thienotriazines and
for the preparation of physiological salt solutions were of ana-
lytical grade procured from local ﬁrms.
Analytical TLC was performed on Silica plates-GF254
(Merck) with visualization by UV or iodine vapors. Melting
points were determined in open capillaries on a Thermonic
Melting point apparatus and are uncorrected. The IR spectra
(KBr, cm1) were run on Perkin Elmer FTIR Spectrophotom-
eter. 1H NMR and 13C NMR (CDCl3/DMSO-d6) spectra were
recorded using Bruker AMX-400 with TMS as internal stan-
dard, MS spectra were recorded on (AMD-604) and elemental
analyses were performed on Carlo Erba 1108 elemental ana-
lyzer and were within ±0.4% of theoretical values.
2.2. Test compounds
2.2.1. Synthesis of thienotriazines
The starting compounds 2-amino-3-(N-substituted carboxa-
mido)-4,5-tetramethylene thiophenes, CP-3a, CP-5a and CP-
8a were synthesized in three steps by the adaptation of well
known and versatile Gewald reaction (Gewald et al., 1966).
Later, the compounds CP-3a, CP-5a and CP-8a were diazo-
tized to yield a series of 3-substituted amino-5,6-tetramethyl-
ene thieno[2,3-d] [1,2,3]-triazin-4(3H)-ones, namely CP-3,
CP-5 and CP-8, respectively. In this reaction, the starting com-
pounds 2-amino-3-(N-substitutes carboxamido)-4,5-tetra-
methylene thiophenes (CP-3a, CP-5a and CP-8a) react with
NaNO2 in the presence of HCl to give respective triazine-4-
ones.
2.2.2. General procedure for the syntheses of 2-amino-3-(N-
substituted carboxamido/carboxanilido)-4,5-tetramethylene
thiophenes (CP-3a, CP-5a, CP-8a)
A mixture of appropriate active methylenic ketone (0.04 mol),
substituted cyano acetamide/acetanilide (0.04 mol), ammo-
nium acetate (2 g) and glacial acetic acid (2 ml) in cyclohexane
(80 ml) was reﬂuxed for 10 h in a Dean stark apparatus with an
arrangement for water separation. The reaction mixture was
cooled, diluted with cyclohexane and washed successively with
water, 10% aqueous sodium carbonate solution, and dried
over anhydrous sodium sulfate. The solvent was removed un-
der vacuum. The crude alpha (N-substituted carboxamido/car-
boxanilido) acetonitrile derivative thus obtained was employed
directly for further reaction.
To a mixture of the above crude intermediate, sulfur
(0.04 mol) in ethanol (40 ml) and diethylamine (4.0 ml) was
added drop wise with stirring. The mixture was stirred for
1 h at 45–50 C, chilled overnight and the solid obtained was
ﬁltered, washed with ethanol to yield yellow crystalline solids.
Recrystallized from suitable solvents. Yield 45–50%.
2.2.2.1. General method for the syntheses of 4,5-tetramethylene
thieno [2,3-d] [1,2,3]-triazin-4(3H)-ones (CP-3, CP-5, CP-8).
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boxamido/carboxanilido)-4,5-substituted thiophenes (CP-3a,
CP-5a, CP-8a) (0.01 mol) in 30 ml of glacial acetic acid was
warmed until the starting material dissolved. The mixture was
cooled to room temperature, 20 ml of concentrated HCl was
added and the reaction mixture was cooled to a temperature be-
low 5 C. To this mixture an ice cold solution of NaNO2
(0.03 mol) in water (25 ml) was added drop wise with constant
stirring. Temperature was maintained below 5 C. The product
separated as bright yellow solid, which was ﬁltered, dried and
washed with methanol to obtain pure triazines (CP-3, CP-5,
CP-8). The synthetic route employed for the synthesis of the title
compounds is outlined in Fig. 1. The physical properties and ele-
mental analysis of CP-3, CP-5 and CP-8 are given in Table 1.
2.2.3. Spectral data
CP-3a: Melting Point: 112–114 C, yield: 47%, MS (%): 283
(M+ 100.0%), 284.08(17.7%), 285.07(4.4%), 285.08(1.8%),
284.07(1.8%).
IR max cm1: Ar-CH 3035.23; -Ali-CH 2982.54; Arom
C‚C 1498.63; –CO– 1692; (C–N) 759.23.
1H NMR (CDCl3): 7.25–7.5 (m, 5H, Ar-H), 2.0–3.0 (m, 8H,
tetramethylenic protons), 1.5 (m, 4H, methylenic protons).
13C NMR (DMSO-d6): 164.5, 138.5, 136.5, 135.6, 128.5,
125.5, 125.7, 122.3, 115.5, 25.5, 23.4, 20.5.
CP-5a: Melting point: 138–140 C, yield: 65%, MS (%):
297.80 (M+) (100.0%), 298.69(17.3%), 299.88(4.5%), 299.10
(1.4%), 298.29(1.1%).
IR max cm1: Ar-CH 3013.34; -Ali-CH 2963.25; Arom
C‚C1507.26; –CO– 1684; (C–N) 742.25.
1H NMR (CDCl3): 7.3–7.4 (d, 2H, Ar-H), 7.1 (s, 1H,
Arom), 6.7 (s, 1H, Arom), 2.4 (s, 3H, methyl protons), 1.7
(m, 4H, methylenic protons), 2.2 (m, 4H, methylenic protons).
13C NMR (DMSO-d6): 164.7, 138.5, 136.7, 135.6, 134.9,
127.4, 126.4, 125.7, 123.4, 121.3, 115.3, 25.6, 23.4, 20.4, 15.7.Figure 1 General experimental scheme for thCP-8a: Melting point: 110–112 C, yield: 62%, MS (%):
317 (M+) (100.0%), 319.04(32.5%), 318.04(18.6%), 320.04
(6.4%), 319.03(4.4%), 321.04(1.4%), 319.05(1.3%).
IR max cm1: Ar-CH 3098.35; -Ali-CH 2968.57; Arom
C‚C 1508.24; –CO– 1688; (C–N) 7734.2.
1H NMR (CDCl3): 7.8 (d, 2H, Arom), 7.2 (d, 2H, Arom),
2.8 (m, 4H, methylenic protons), 1.6 (m, 8H, methylenic
protons).
13C NMR (DMSO-d6): 164.5, 138.5, 136.5, 135.6, 134.5,
129.5, 125.5, 125.7, 122.3, 118.5, 115.5, 25.5, 23.4, 20.5.
2.3. Experimental animals
Guinea pigs of either sex (200–300 g) and female swiss albino
mice (18–22 g) were purchased from Bioneeds, Nelamangala,
Tumkur, India. They were housed in a separate room in ani-
mal facility of PES College of Pharmacy. Mice were main-
tained in polypropylene cages, while guinea pigs were
maintained in stainless steel cages at a temperature of
25 ± 1 C and relative humidity of 45–55% in a clean environ-
ment under 12 h light–dark cycle. The animals had free access
to food pellets (Pranav Agro Industry, Bangalore, India) and
puriﬁed water ad libitum.
All the experimental protocols were approved by Institu-
tional Animal Ethics Committee (IAEC) of PES College of
Pharmacy (No. PESCP/IAEC/03/2005-06) and were con-
ducted according to the guidelines of CPCSEA, India.
3. Experimental protocol
3.1. Acute toxicity studies
The acute intraperitoneal toxicity for the test compounds was
determined in female, nulliparous and non pregnant swiss albi-
no mice weighing 18–22 g. After administration of differente synthesis of thieno 1,2,3 triazine-4-ones.
Table 1 Physical properties and elemental analysis of CP-3, CP-5 and CP-8.
Compound Mol. formula Mol. wt R M.P (C) % Yield Rf value (solvent CHC13:MeOH)
(70:30)
Elemental analysis
Theoretical Actual
CP-3 Ci5H13N3OS 283 112–114 47 0.71 C = 63.58
H= 4.62
N= 14.84
S = 11.32
C = 6i.60
H = 4.63
N = 14.82
S = 11.33
CP-5 C16H15N3OS 297 138–140 64 0.80 C = 64.62
H= 5.0S
N= 14.14
S = 10.77
C = 64.59
H = 5.07
N = 14.12
S = 10.78
CP-8 C15H12N3OSCl 317.5 110–112 62 0.72 C = 56.69
H= 3.81
N= 13.22
S = 10.07
C = 56.60
H = 3.S2
N = 13.21
S = 10.09
48 G.L. Viswanatha et al.doses of test compounds, the mortality with each dose was
noted at 48 h (acute) and 14 days (chronic) as per OECD
guideline no. 425. LD50 was calculated using AOT425 stat pro-
gram (http://www.oecd.org/dataoecd/17/51/1948378.pdf).
3.2. Antihistaminic activity
3.2.1. In vitro antihistaminic activity by using isolated guinea pig
ileum
The guinea pig was sacriﬁced after 24 h of fasting, the ileocae-
cal junction was exposed by giving the midline abdominal inci-
sion and the ileum was isolated by discarding the terminal
10 cm length nearer to ileocaecal junction, the lumen of the
isolated ileum was thoroughly cleaned by using a warm tyrode
solution with the help of a 50 ml volumetric pipette. A small
piece of the ileum with 2–4 cm length was cut; at the two oppo-
site ends a thread is passed through the lumen with the help of
a ﬁne suturing needle and tied securely without occluding the
lumen. One end of the segment is secured tightly to the tissue
holder and transferred to the organ bath already ﬁlled with
Tyrode solution of following composition: 136.9 mM NaCl,
11.9 mM NaHCO3, 2.68 mM KCl, 1.05 mM MgSO4, 1.8 mM
CaCl2, 0.37 mM NaH2PO4 and 5.6 mM glucose. The solution
was kept at 37 ± 1 C and it was continuously aerated with
95% O2 and 5% CO2. The pH of the solution was maintained
at 7.4, The tissue holder is ﬁxed in position with clamps and
the long thread from the tissue is tied to the force transducer
(T 305) connected to student physiograph (Bio-Devices,
Ambala, India) against a constant load of 1 g. The tissue
was allowed to stabilize for a period of 30 min, after which
concentration response curves (CRC) to histamine (contact
time 30 s) were constructed by a cumulative addition of log
increment dose of histamine in the absence or presence of
antagonists. Antagonists were incubated with ileum for
30 min before the addition of cumulative concentrations of his-
tamine (Shames et al., 1999).Mean CRCs to contraction rate were analyzed by the equa-
tion (given below) using non-linear regression of GraphPad
Prism trial version software (GraphPad Software Inc., San
Diego, USA).
Y ¼ Bottomþ ðTop BottomÞ
1þ 10ðlogEC50 XÞP
where X is logarithm of molar concentration of the relaxant, Y
is the response produced by the agonist and P is the slope of
the CRCs. EC50 is the concentration (M) of the relaxant that
produces 50% of its maximum response and pEC50 is the neg-
ative logarithm of EC50.
Agonist concentration ratios(r) were determined from the
EC50 on the CRCs with or without antagonists. The plot of
log [agonist concentration (dose) ratio (r)  1] vs. log [antago-
nist] was analyzed by linear regression.
Antagonism was considered to be competitive if the slope
(m) of regression line was not signiﬁcantly different from unity.
In some cases a mean pA2 value was obtained from individuals
estimated using the equation.
pA2 ¼ logðr 1Þ  log½antagonist
In the cases where the slope or regression line signiﬁcantly
differed from unity, the value obtained from the above equa-
tion was pKB rather than pA2. A statistically signiﬁcant differ-
ence between two means was analyzed using one-way analysis
of variance followed by the Tukey test, where comparison was
made to the same control group. P< 0.05 was considered
signiﬁcant.
3.2.2. In vivo antihistaminic activity by histamine induced
bronchospasm in guinea pigs
Guinea pigs were treated with vehicle/test compounds/Chlor-
pheniramine maleate (2 mg/kg) intraperitoneally. After 30 min
of the vehicle/test drug/CPM treatment, the bronchospasm
was induced by exposing the animals to 2% histamine acid
Synthesis and antihistaminic activity of 3H-benzo [4,5] thieno [2,3-d][1,2,3] triazin-4-ones 49phosphate under constant pressure and rate (1 kg/cm2) in a his-
tamine chamber (24 · 14 · 24 cm, INCO, Ambala, India) made
up of perplex glass, the preconvulsive time (PCT) was deter-
mined from the time of exposure to the onset of dyspnoea lead-
ing to the appearance of convulsions which is known as
preconvulsive dyspnoea (PCD).
As soon as the PCD were noted, the animals were removed
from the chamber and placed in fresh air. The animals which
withstand exposure to histamine aerosol for 15 min were con-
sidered to be completely protected (Gopumadhavan
et al.,2005).
3.2.3. CNS depressant activity of CPM and test drug by
actophotometer
Each animal was placed individually on Actophotometer
(INCO, Ambala, India) and basal locomotor activity score
of all the animals were noted. Mice were injected with test/
CPM/vehicle and after 30 min each animal was tested for loco-
motor activity score for 10 min and the percentage decrease in
motor activity was calculated (Kulkarni, 2005).
3.2.4. Statistical analysis
The results of various studies were expressed as mean ±
S.E.M. Data analysis was done by one way analysis of vari-
ance (ANOVA) followed by Tukey test. Probability values of
0.05 (p< 0.05) or less were considered statistically signiﬁcant.Figure 2 Effect of CP-3, CP-5, CP-8 and CPM on histamine indu
percentage decrease in contractions induced by histamine.4. Results
4.1. Acute toxicity studies
Intraperitoneal administration of CP-3, CP-5 and CP-8 at 55
and 175 mg/kg dose levels did not show any toxic signs during
short term and long term observation period. However, at
550 mg/kg, i.p. dose of CP-3, CP-5 and CP-8 produced
100% mortality during the short-term observation period.
LD50 value of all the test drugs was found to be 310 mg/kg.
4.2. Antihistaminic activity
4.2.1. In vitro studies
CP-3, CP-5, CP-8 and CPM shifted the CRCs of histamine
toward the right with a change in EC50 values of histamine.
The schild plot yielded a line with a slope close to unity for
CP-5, CP-8 and CPM in guinea pig ileum preparation, indi-
cating that the antagonists were competitive in nature for
H1-receptors. However, the slope of the schild plot was sig-
niﬁcantly different from unity for the test drug CP-3, indi-
cating non competitive antagonism, the rightward shift of
histamine CRCs and schild plots for histamine in the pres-
ence of CP-3, CP-5, CP-8 and CPM are shown in the
Figs. 2 and 3, respectively, the EC50 and pA2 values are
shown in Table 2.ced contractions on guinea pig ileum. Results are expressed as
Figure 3 Schild plot for CP-3, CP-5, CP-8 and CPM.
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All the test drugs (CP-3, CP-5 and CP-8) and chlorphenir-
amine maleate have shown the mean increase in exposition
time against histamine challenge compared to control group
(p< 0.001). All the test drugs (10 mg/kg) and standard anti-
histaminic chlorpheniramine maleate (2 mg/kg) have offered
signiﬁcant (p< 0.001) protection against PCD compared to
control group, However, signiﬁcant antihistaminic effect wasTable 2 Effect of CPM, CP-3, CP-5 and CP-8 on contractions ind
Treatment EC50 (lM)
Histamine alone 4.65 (4.07–5.03)
CP-3 (100 nm) 1.88 (5.21–6.81)
CP-3 (200 nm) 3.53 (1.40–8.90)
CP-3 (300 nm) 0.0002 (5.97–126.3)
CP-5 (100 nm) 3.36 (1.27–8.90)
CP-5 (200 nm) 6.94 (2.66–1.81)
CP-5 (300 nm) 9.20 (4.93–1.71)
CP-8 (100 nm) 5.33 (1.69–1.68)
CP-8 (200 nm) 9.95 (1.91–5.15)
CP-8 (300 nm) 1.42 (8.46–2.40)
CPM (300 pm) 1.88 (5.21–6.81)
CPM (1 nm) 6.64 (2.48–1.77)
CPM (3 nm) 2.41 (8.54–6.80)
The values in the parenthesis indicate EC50 range at 95% conﬁden
mean ± S.E.M.not observed in lower dose (5 mg/kg) of test compounds.
The results are shown in the Table 3.
4.2.3. CNS depressant activity of CPM and test drug by
actophotometer
The standard drug chlorpheniramine maleate has shown a sig-
niﬁcant decrease in the locomotor activity at 10 mg/kg dose
and none of the test drugs (CP-3, CP-5 and CP-8) have shownuced by histamine in isolated guinea pig ileum.
pEC50 pA2/pKB value
6.449 ± 0.237 –
5.724 ± 0.275 10.211 ± 0.42
4.451 ± 0.197
3.561 ± 2.79
5.472 ± 0.208 8.65 ± 0.01
5.158 ± 0.205
5.036 ± 0.133
5.272 ± 0.246 8.50 ± 0.009
5.002 ± 0.352
4.845 ± 0.111
5.724 ± 0.275 10.491 ± 0.038
5.177 ± 0.210
4.617 ± 0.222
ce interval. The values of pEC50 and pA2/pKB are expressed as
Table 3 Effect of CP-3, CP-5 and CP-8 and CPM on histamine induce bronchospasm in guinea pigs.
Sl. no. Groups Onset of PCD (in sec) % Protection against mortality
I Control 195 ± 12.4 0
II CPM (2 mg/kg) 800 ± 25.69*** 100
III CP-3 (5 mg/kg) 225 ± 12.84 100
IV CP-3 10 mg/kg) 860 ± 24.08*** 100
V CP-5 (5 mg/kg) 230 ± 16.73 83.34
VI CP-5 (10 mg/kg) 720 ± 26.83*** 100
VII CP-8(5 mg/kg) 240 ± 17.32 66.65
VIII CP-8 (10 mg/kg) 690 ± 37.14*** 100
Values are expressed as mean ± S.E.M from six guinea pigs. ***P< 0.001; compared with control group using one way ANOVA followed by
Tukey test.
Table 4 Effect of CP-3, CP-5, CP-8 and CPM on spontaneous locomotor activity in mice.
Groups Control CPM treated group (Std)
(10 mg/kg)
CP-3 (50 mg/kg) CP-5 (50 mg/kg) CP-8 (50 mg/kg)
Spontaneous locomotor activity 679.16 ± 21.4 102.66 ± 2.69*** 513.83 ± 6.11*** 484.16 ± 7.12*** 474.66 ± 4.77***
% Inhibition in locomotor activity – 84.88344 24.34 28.71 30.11
Values are expressed as mean ± S.E.M from six mice. ***P< 0.001; compared with control group using one way ANOVA followed by Tukey
test.
Synthesis and antihistaminic activity of 3H-benzo [4,5] thieno [2,3-d][1,2,3] triazin-4-ones 51a signiﬁcant decrease in the locomotor activity at 50 mg/kg
dose compared to CPM treated group, indicating the very less
CNS depression property of test drugs. The results are shown
in Table 4.
5. Discussion
The results of the present investigation indicate that, CP series
of compounds exerts speciﬁc antihistaminic action. However,
in all these preparations histamine manifests its effect by acting
upon H1-receptors (Patnaik et al., 1979). The purpose behind
selecting CPM as a standard for both the models was to ﬁnd
out whether the action of CP series of compounds is dependent
on H1-receptors or not. The compounds were able to antago-
nize the action of histamine on H1-receptors in both the
models.
Histamine has a key role in many physiological processes
including inﬂammation and the drugs that target H1-receptors
have been successful for the treatment of allergy. H1-receptors
are expressed on multiple cell types including endothelial cells
and smooth muscle cells, where they mediate vasodilation and
bronchoconstriction. Antagonists of H1-receptors, such as
diphenhydramine and loratadine have been used for many
years in the treatment of allergic inﬂammatory responses
(Thurmond et al., 2008).In the assessment of H1-receptor anti-
histaminic activity in vitro, the parallel rightward shift in ago-
nist concentration response curves in the presence of increasing
concentrations of antagonist is observed with competitive
antagonists. The occurred inhibition with competitive antago-
nists can be overcome by increasing the concentration of ago-
nist. Finally a maximal effect can be achieved by using
sufﬁcient agonist (Thurmond et al., 2008).
The results of this study indicate a similar rightward shift in
dose response curves of histamine in the presence of test drugs(CP-3, CP-5 and CP-8) and CPM. By increasing the dose of
test drug, the EC50 has increased. The slopes of drugs CP-5,
CP-8 and CPM are near to unity indicating that the antago-
nism of these drugs is competitive in nature whereas the CP-
3 had shown noncompetitive type of antagonism. All the drugs
had shown good antagonistic activity as indicated by their pA2
values. Currently antihistamines (H1-receptor blockers) are not
used as front-line drugs for the treatment asthma; the provoc-
ative similarity between the physiological effects of histamine
and the pathological symptoms of asthma has resulted in an
enduring investigation into the possible utility of antihista-
mines in various models of bronchospasm (Thurmond et al.,
2008). As in the case of above study, the increase in the onset
of PCD (in sec) against histamine challenge was signiﬁcantly
(p< 0.001) increased with the increasing doses of test drugs.
The H1-receptor occupancy in brain is an indicator of cen-
tral side effects of antihistamines (Gupta et al., 2007). The
antagonism of H1-receptors in the brain can lead to side effects
like sedation and impairment of cognitive functions as experi-
enced with ﬁrst generation antihistaminics in the treatment of
allergic disorders (Simons et al., 1996). So we have evaluated
the test drug for sedating potential by using spontaneous loco-
motor activity (Actophotometer) in mice. Based on LD50 value
and therapeutic dose level in in vivo study, the dose range was
selected as ﬁve times that of in vivo therapeutic dose i.e. 10 mg/
kg in case of CPM and 50 mg/kg in case of test drugs. CPM
has signiﬁcantly decreased the spontaneous locomotor activity
in mice compared to control but all the three test drugs have a
very little effect on spontaneous locomotor activity compared
to standard drug CPM.
The overall study has suggested that all the three test drugs
(CP-3, CP-5 and CP-8) possess very good antihistaminic activ-
ity, the CP-5 and CP-8 were found to possess competitive
antagonism and CP-3 was found to possess non-competitive
52 G.L. Viswanatha et al.antagonism at H1-receptor site and having very low sedative
potential compared to standard drug CPM.Conﬂict of interest statement
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